Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 349

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

Martínez, Esteban, Blanco, José L., Arnaiz, Juan A., Pérez-Cuevas, José B., Mocroft, Amanda, Cruceta, Anna, Marcos, María A., Milinkovic, Ana, García-Viejo, Miguel A., Mallolas, Josep, Carné, Xavier, Phillips, Andrew, Gatell, José M.·2001·AIDS

Abstract

OBJECTIVES: To assess the incidence and risk factors for hepatotoxicity associated with nevirapine. DESIGN: A prospective cohort study in a teaching and referral hospital involving all consecutive patients who were prescribed a nevirapine-containing antiretroviral regimen between September 1997 and May 2000. METHOD: Cutaneous and hepatic adverse reactions and clinical hepatitis were assessed. Blood analysis including plasma HIV-1 RNA CD4 cell counts, liver chemistry tests, and serology for hepatitis B and C viruses. Hepatotoxicity was defined as an increase of at least threefold in serum alanine aminotransferase or aspartate aminotransferase levels compared with baseline values. RESULTS: Of a total of 610 patients, 82 (13.4%) were antiretroviral naive when commencing nevirapine, and 46.2 and 8.9% were coinfected with hepatitis C and B viruses, respectively. Median duration of exposure to nevirapine was 8.7 months (interquartile range 3.4--14.3). Hepatotoxicity developed in 76 (12.5%), an incidence of 13.1/100 person-years. Kaplan--Meier estimated incidence of hepatotoxicity at 3, 6 and 12 months was 3.7, 9.7 and 20.1%, respectively. In seven (1.1%) patients, hepatotoxicity was associated with clinical hepatitis, which was reversible upon discontinuation of therapy. Multivariate analysis identified the duration of prior exposure to antiretroviral drugs, hepatitis C virus, and higher baseline levels of alanine aminotransferase as independent risk factors for hepatotoxicity. CONCLUSIONS: Hepatotoxicity but not clinical hepatitis was common in HIV-1-infected patients receiving nevirapine-containing regimens and the incidence steadily increased over time. Prolonged exposure to any antiretroviral therapy, coinfection with hepatitis C virus and abnormal baseline levels of alanine aminotransferase identified patients at a higher risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00002030-200107060-00007

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 349

Metadata

Authors
Martínez, E., Blanco, J. L., Arnaiz, J. A., Pérez-Cuevas, J. B., Mocroft, A., Cruceta, A., Marcos, M. A., Milinkovic, A., García-Viejo, M. A., Mallolas, J., Carné, X., Phillips, A., & Gatell, J. M.
Venue
AIDS
Published
2001-07
Volume
15
Issue
10
Pages
1261-1268
ISSN
0269-9370 (ISSN-L)
OpenAlex
W2013907757
Cited by
349
References
11
FWCI
24.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. https://app.cochat.ai/papers/10.1097/00002030-200107060-00007
The paper
Martínez, E., Blanco, J. L., Arnaiz, J. A., Pérez-Cuevas, J. B., Mocroft, A., Cruceta, A., Marcos, M. A., Milinkovic, A., García-Viejo, M. A., Mallolas, J., Carné, X., Phillips, A., & Gatell, J. M. (2001). Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. https://doi.org/10.1097/00002030-200107060-00007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.